



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid Drug Utilization Review (DUR) Board
Thursday, March 22, 2018, 2:00pm
DMAS Board Room 13th Floor
Agenda

1. **Call to Order and Introductions** – Bill Rock, PharmD, Chair
2. **Minutes**
 - a. Approval of Minutes from November 9, 2017 meeting
3. **New Drugs**
 - a. Calquence® (acalabrutinib)
 - b. Gocovri™ (amantadine extended-release)
 - c. Hemlibra® (emicizumab-kxwh)
 - d. Juluca™ (dolutegravir/rilpivirine)
 - e. Prevymis™ (letermovir)
 - f. Rebinyn® (coagulation factor ix (recombinant), glycopegylated)
 - g. Verzenio™ (abemaciclib)
 - h. Ximino™ (minocycline)
 - i. New drugs: New Generics; PDL-eligible; physician-administered injectables
4. **RetroDUR Criteria Estimates**
5. **Topics for Discussion**
 - a. Orphan Drugs
 - b. Acute Dosing of Proton Pump Inhibitors
 - c. Gender Edit for Point of Sale System
 - d. Pediatric and Adult Opioid Utilization
 - j. Naloxone Utilization Review
 - k. Analysis of Compounded Medications
 - l. DUR Quarterly Newsletter



COMMONWEALTH of VIRGINIA
Department of Medical Assistance Services
DRUG UTILIZATION REVIEW PROGRAM

- 6. Reports**
 - a. ProDUR
 - b. RetroDUR
 - c. Utilization Analysis
 - d. Top Diagnoses by Age
 - e. AAP Report
- 7. Adjournment**

DRAFT